Fmr LLC Decreases Holdings in Lexicon Pharmaceuticals, Inc. (LXRX)

Fmr LLC reduced its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 2.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,503,980 shares of the biopharmaceutical company’s stock after selling 370,800 shares during the period. Fmr LLC owned 14.64% of Lexicon Pharmaceuticals worth $165,427,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Schwab Charles Investment Management Inc. raised its stake in shares of Lexicon Pharmaceuticals by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,061 shares of the biopharmaceutical company’s stock worth $2,893,000 after purchasing an additional 14,426 shares during the last quarter. BlackRock Inc. raised its stake in shares of Lexicon Pharmaceuticals by 4.6% in the second quarter. BlackRock Inc. now owns 4,422,293 shares of the biopharmaceutical company’s stock worth $53,066,000 after purchasing an additional 195,461 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new position in shares of Lexicon Pharmaceuticals in the second quarter worth about $164,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Lexicon Pharmaceuticals in the second quarter worth about $205,000. Finally, Northern Trust Corp raised its stake in shares of Lexicon Pharmaceuticals by 2.1% in the second quarter. Northern Trust Corp now owns 584,393 shares of the biopharmaceutical company’s stock worth $7,013,000 after purchasing an additional 12,289 shares during the last quarter.

Shares of LXRX stock opened at $7.11 on Friday. The company has a debt-to-equity ratio of 8.85, a current ratio of 2.90 and a quick ratio of 2.83. The company has a market cap of $788.09 million, a P/E ratio of -5.60 and a beta of 0.75. Lexicon Pharmaceuticals, Inc. has a twelve month low of $7.04 and a twelve month high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.07. The company had revenue of $6.90 million during the quarter, compared to analysts’ expectations of $12.56 million. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. Lexicon Pharmaceuticals’s quarterly revenue was down 74.3% on a year-over-year basis. During the same period last year, the business earned ($0.29) earnings per share. As a group, equities analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.29 earnings per share for the current year.

Several research analysts recently weighed in on LXRX shares. BidaskClub cut Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 4th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 28th. Citigroup reduced their price target on Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, November 2nd. Gabelli reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. Finally, Cowen reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $25.25.

TRADEMARK VIOLATION WARNING: “Fmr LLC Decreases Holdings in Lexicon Pharmaceuticals, Inc. (LXRX)” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/12/08/fmr-llc-decreases-holdings-in-lexicon-pharmaceuticals-inc-lxrx.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: What are retained earnings?

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply